Goldstein Advisors LLC Increases Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Goldstein Advisors LLC raised its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 19.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 30,425 shares of the company’s stock after purchasing an additional 5,000 shares during the period. Goldstein Advisors LLC’s holdings in Xeris Biopharma were worth $87,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in XERS. Vanguard Group Inc. increased its stake in Xeris Biopharma by 7.3% in the first quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock valued at $16,810,000 after purchasing an additional 519,897 shares during the last quarter. NEA Management Company LLC purchased a new position in shares of Xeris Biopharma during the first quarter worth approximately $926,000. Renaissance Technologies LLC grew its position in shares of Xeris Biopharma by 33.9% during the second quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock worth $3,041,000 after acquiring an additional 342,300 shares during the last quarter. Rosalind Advisors Inc. grew its position in shares of Xeris Biopharma by 10.6% during the second quarter. Rosalind Advisors Inc. now owns 3,120,170 shares of the company’s stock worth $7,020,000 after acquiring an additional 300,000 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Xeris Biopharma by 23.0% during the second quarter. Bank of New York Mellon Corp now owns 428,554 shares of the company’s stock worth $964,000 after acquiring an additional 80,015 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Price Performance

NASDAQ:XERS opened at $3.20 on Friday. The firm’s fifty day moving average price is $2.87 and its 200 day moving average price is $2.40. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.46 and a 1-year high of $3.39. The firm has a market cap of $474.42 million, a price-to-earnings ratio of -6.81 and a beta of 2.76.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. The firm had revenue of $48.07 million for the quarter, compared to analyst estimates of $46.80 million. During the same period last year, the firm posted ($0.14) EPS. As a group, analysts expect that Xeris Biopharma Holdings, Inc. will post -0.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Xeris Biopharma in a research report on Thursday, August 15th.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.